山东年轻人为什么尿酸会高(济南运动能治疗痛风吗) (今日更新中)

BEIJING, Aug. 22 (Xinhuanet) -- Researchers have discovered how a human egg captures an incoming sperm for fertilization, paving the way to help couples suffering from infertility, according to media reports on Monday.An international team of researchers found that a sugar chain known as the sialyl-lewis-x sequence (SLeX) makes the outer coat of the egg “sticky,” which has proven to be helpful in binding the egg and the sperm.As a result, this observation has filled in a huge gap in the understanding of fertility and provides hope for ultimately helping couples who currently cannot conceive.Scientists and doctors know that a sperm identifies an egg when proteins on the head of the sperm match and bind to a series of specific sugars in the egg’s outer coating. With a successful match of proteins, the outside surfaces of the sperm and egg then bind together before merging, which is then followed by delivery of sperm’s DNA into egg.To identify this molecules, the researchers used ultra-sensitive mass-spectrometric imaging technology to observe and identify which molecules are most likely to be key in the binding process.They experimented with a range of synthesised sugars in the laboratory and found that it is SLeX that specifically binds sperm to an egg.According to the World Health Organisation, infertility affects about 15 percent of reproductive-aged couples around the world and almost one in every seven couples in Britain has problems conceiving a child for various reasons.

CHENGDU, Sept. 3 (Xinhua) -- A list of this year's top 500 Chinese enterprises was unveiled in the city of Chengdu in southwest China's Sichuan Province on Saturday.The Sinopec Group was ranked first, with last year's revenues reaching 1.97 trillion yuan (307.81 billion U.S. dollars), followed by the China National Petroleum Corp. and State Grid Corp., whose revenues hit 1.72 trillion yuan and 1.53 trillion yuan last year, respectively.The rest of the top 10 was rounded out by the Industrial and Commercial Bank of China, China Mobile, China Railway Group, China Railway Construction Corp., China Construction Bank, China Life Insurance Co. and Agricultural Bank of China.The list is the 10th of its kind to be jointly released by the China Enterprise Confederation and the China Enterprise Directors Association. The threshold for entering the list was raised to 14.2 billion yuan in revenues, an increase over the 11.08-billion-yuan threshold used during the previous year.Revenues for China's top 500 companies rose 31.6 percent year-on-year to 36.31 trillion yuan in 2010, while their total assets increased by 18.4 percent to 108.1 trillion yuan, the two organizations said.The companies reported profits of 2.08 trillion yuan for last year, a rise of 38.67 percent from one year earlier.They paid 2.73 trillion yuan in taxes in 2010, accounting for 37.3 percent of the country's total tax revenues.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SYDNEY, July 1 (Xinhua) -- Breastfeeding mothers should limit their use of codeine-containing painkillers to four days as they can cause harm, an Australian doctor warned on Friday.The warning is being discussed at a meeting of anesthetists in Sydney."New mothers should limit their use of codeine-containing painkillers to no more than four days and, if they feel drowsy while taking this medication, cease its use and have their baby examined by a doctor for signs of drowsiness," Sydney's Royal North Shore Hospital anesthetist Dr. Gavin Pattullo said."This is because codeine needs to be metabolized by the liver into morphine to offer pain relief and this liver conversion process is very unpredictable," Pattullo said."Some patients' livers produce large amounts of morphine after taking codeine, causing drowsiness, while others fail to produce any morphine at all."Pattullo said for breastfeeding mothers, a large dose of morphine could make its way into the baby and result in the baby's death by overdose."While new mums shouldn't be unnecessarily alarmed, they need to be aware that codeine-containing painkillers in certain circumstances can cause harm," he said.Breastfeeding mothers are being advised to see a doctor if their baby gets sleepy while taking the painkillers.

JOHANNESBURG, June 1 (Xinhua) -- An estimated 2 million adolescents ages 10 to 19 are living with HIV, with 86 percent of them from sub-Saharan Africa, according to a global report on HIV prevention launched in Johannesburg on Wednesday.For the first time, the world gets to see the number of adolescents between the ages of 10 to 19 living with HIV in the report named Opportunity in Crisis: Preventing HIV from early adolescence to young adulthood.The report is a jointly publication by the United Nations Children's Fund (UNICEF), UNAIDS, the United Nations Educational, Scientific and Cultural Organization (UNESCO), the United Nations Population Fund (UNFPA), the International Labor Organization (ILO) , the World Health Organization (WHO) and World Bank.According to the report, people aged 15-24 accounted for 41 percent of new infections over the age of 15 in 2009. Worldwide, an estimated 5 million young people in that age group were living with HIV in 2009. Most of them live in sub-Saharan Africa. Globally, young women make up more than 60 percent of all young people living with HIV. In sub-Saharan Africa that rate jumped to 72 percent.Despite these challenges, the report acknowledges that some progress has been made in preventing new infections among young people."In many high-burden countries, HIV prevalence and incidence have declined among young people. While in 2001 there were 5.7 million young people living with HIV, the figure stands at 5 million (in 2009)," said the UNICEF eastern and southern Africa regional director, Elhadj As Sy, at the media briefing.He pointed that sexual transmission and injection drug use remain the major modes of transmission of HIV among young people. Early sexual debut, early pregnancy and early experiences with drug use all raise risks for HIV infection.The report reveals that unemployment and poverty are reported as the main reasons young people enter the sex trade. Worldwide, many young people driven by economic pressure, exploitation, social exclusion and lack of family support turn to commercial sex and injecting drug use.In 2001, the world made a commitment to reduce the prevalence of HIV among young people by 25 percent by 2010. The actual reduction achieved (from 5.7 million to 5 million) is 12 percent, and it represents less than half the target percentage."To avoid the current programming failures, we have to adopt a ' Continuum of Prevention Approach'." said Lina Mousa, deputy director of UNFPA Africa Regional Office."This continuum of prevention must be reflected in national HIV strategic plans, poverty reduction strategies and global fund proposals. This response must be developed with and for young people so that they own the response together with their communities," she added.To build this continuum of prevention for adolescents and young people, the reports outlined nine specific recommendations including providing young people with information and comprehensive sexuality education, strengthening child protection and social protection measures, engaging communities in shaping a positive social environment that promotes healthy behavior, establishing laws and policies that respect young people's rights.

来源：资阳报